Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Mangiola

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironmentSamuel S Widodo, Ryan A Hutchinson, Yitong Fang, et al.
Biotechnology Advances|July 31, 2013
Insights into the immuno-molecular biology of Angiostrongylus vasorum through transcriptomics--prospects for new interventionsBrendan R E Ansell, Manuela Schnyder, Peter Deplazes, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 25, 2022
Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organizationMarija Dinevska, Samuel S Widodo, Liam Furst, et al.
Experimental Cell Research|December 19, 2018
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistanceRyan J Atkins, Stanley S Stylli, Natalie Kurganovs, et al.
European Urology Focus|May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate CancerEdmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Prostate Cancer and Prostatic Diseases|June 10, 2021
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancerPatrick McCoy, Stefano Mangiola, Geoff Macintyre, et al.
Genome Medicine|August 19, 2020
Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progressionEdmund Lau, Patrick McCoy, Fairleigh Reeves, et al.
Cancer Immunology Research|December 11, 2020
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in MelanomaEmily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, et al.
Cellular and Molecular Life Sciences : CMLS|August 4, 2019
Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii)Amanda L Patchett, Tim H H Coorens, Jocelyn Darby, et al.
JCO Precision Oncology|July 29, 2021
Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation TherapyMarek Cmero, Natalie J Kurganovs, Ryan Stuchbery, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Cancer Immunology, Immunotherapy : CII|January 3, 2021
Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironmentSamuel S Widodo, Ryan A Hutchinson, Yitong Fang, et al.
Biotechnology Advances|July 31, 2013
Insights into the immuno-molecular biology of Angiostrongylus vasorum through transcriptomics--prospects for new interventionsBrendan R E Ansell, Manuela Schnyder, Peter Deplazes, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 25, 2022
Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organizationMarija Dinevska, Samuel S Widodo, Liam Furst, et al.
Experimental Cell Research|December 19, 2018
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistanceRyan J Atkins, Stanley S Stylli, Natalie Kurganovs, et al.
European Urology Focus|May 20, 2019
Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate CancerEdmond M Kwan, Heidi Fettke, Maria M Docanto, et al.
Prostate Cancer and Prostatic Diseases|June 10, 2021
MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancerPatrick McCoy, Stefano Mangiola, Geoff Macintyre, et al.
Genome Medicine|August 19, 2020
Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progressionEdmund Lau, Patrick McCoy, Fairleigh Reeves, et al.
Cancer Immunology Research|December 11, 2020
Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in MelanomaEmily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, et al.
Cellular and Molecular Life Sciences : CMLS|August 4, 2019
Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii)Amanda L Patchett, Tim H H Coorens, Jocelyn Darby, et al.
JCO Precision Oncology|July 29, 2021
Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation TherapyMarek Cmero, Natalie J Kurganovs, Ryan Stuchbery, et al.
Pageof 4